SSGXVIII/AIO Investigators and Authors: Odd R. Monge, MD, Department of Oncology and Radiotherapy, Haukeland University Hospital, Bergen, Norway; Petri Bono, MD, Department of Oncology, Helsinki University Central Hospital, Helsinki, Finland; Raija Kallio, MD, Department of Oncology and Radiotherapy, Oulu University Hospital, Oulu, Finland; Thor Alvegård, MD, Department of Biomedical Engineering and Computational Science, Department of Cancer Epidemiology, Lund University, Lund, Sweden.
Risk factors for gastrointestinal stromal tumor recurrence in patients treated with adjuvant imatinib
Article first published online: 15 APR 2014
© 2014 The Authors. Cancer published by Wiley Periodicals, Inc. on behalf of American Cancer Society.
This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.
Volume 120, Issue 15, pages 2325–2333, August 1, 2014
How to Cite
Joensuu, H., Eriksson, M., Hall, K. S., Hartmann, J. T., Pink, D., Schütte, J., Ramadori, G., Hohenberger, P., Duyster, J., Al-Batran, S.-E., Schlemmer, M., Bauer, S., Wardelmann, E., Sarlomo-Rikala, M., Nilsson, B., Sihto, H., Ballman, K. V., Leinonen, M., DeMatteo, R. P. and Reichardt, P. (2014), Risk factors for gastrointestinal stromal tumor recurrence in patients treated with adjuvant imatinib. Cancer, 120: 2325–2333. doi: 10.1002/cncr.28669
- Issue published online: 21 JUL 2014
- Article first published online: 15 APR 2014
- Manuscript Accepted: 10 FEB 2014
- Manuscript Revised: 9 FEB 2014
- Manuscript Received: 21 DEC 2013